医学临床研究
  2025年7月11日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (5): 690-692    DOI: 10.3969/j.issn.1671-7171.2022.05.014
  论著 本期目录 | 过刊浏览 | 高级检索 |
支持性-表达性团体心理干预联合棕榈酸帕利哌酮治疗急性期首发精神分裂症患者的临床疗效
赵文青
宝鸡市康复医院,陕西 宝鸡 721000
Clinical Efficacy of Supportive Expressive Group Psychological Intervention Combined with Paliperidone Palmitate in the Treatment of Acute First-Episode Schizophrenia
ZHAO Wen-qing
Baoji Rehabilitation Hospital,Baoji Shaanxi 721000
全文: PDF (1190 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨支持性-表达性团体心理干预联合棕榈酸帕利哌酮治疗急性期首发精神分裂症患者的临床效果。【方法】回顾性分析2019年1月至2021年2月本院收治的98例急性期首发精神分裂症患者的临床资料,根据治疗方法的不同将其分为观察组和对照组,每组49例。对照组口服棕榈酸帕利哌酮缓释片治疗,观察组在对照组的基础上给予支持性-表达性团体心理干预,比较两组患者治疗前后正负性情绪状态量表(PANAS)、社会功能缺陷筛选量表(SDSS)、精神分裂症病人生活质量量表(SQLS)评分。【结果】治疗1个月、治疗3个月,两组患者正性情绪评分高于治疗前,负性情绪评分低于治疗前,且两组患者治疗3个月与治疗1个月,以及两组组间比较,差异均有统计学意义(均P<0.05);两组患者社会功能缺陷评分低于治疗前,且两组患者治疗3个月与治疗1个月,以及两组组间比较,差异均有统计学意义(均P<0.05);两组患者动力与精力、心理社会、症状和副作用评分均低于治疗前,且两组患者治疗3个月与治疗1个月,以及两组组间比较,差异均有统计学意义(均P<0.05)。【结论】支持性-表达性团体心理干预联合棕榈酸帕利哌酮可较好改善急性期首发精神分裂症患者情绪状态,恢复患者社会功能,提高患者生活质量。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
赵文青
关键词 精神分裂症/药物疗法急性病精神分裂症心理学棕榈酸帕利哌酮/治疗应用    
Abstract:【Objective】 To explore the clinical effect of supportive expressive group psychological intervention combined with paliperidone palmitate in the treatment of acute first-episode schizophrenia. 【Methods】 The clinical data of 98 patients with acute first-episode schizophrenia treated in our hospital from January 2019 to February 2021 were analyzed retrospectively. According to different treatment methods, they were divided into observation group and control group, with 49 cases in each group. The control group was treated with paliperidone palmitate sustained-release tablets, and the observation group was given supportive expressive group psychological intervention on the basis of the control group. The scores of positive and negative emotional state scale (PANAS), social function deficiency screening scale (SDSS) and quality of life scale for patients with schizophrenia (SQLS) were compared between the two groups before and after treatment. 【Results】 After one month and three months of treatment, the positive emotion score of the two groups was higher than that before treatment, and the negative emotion score was lower than that before treatment. There was significant difference between the two groups after three months of treatment and one month of treatment, as well as between the two groups (all P<0.05); The social function defect score of the two groups was lower than that before treatment, and there was significant difference between the two groups after 3 months of treatment and 1 month of treatment, as well as between the two groups (all P<0.05); The scores of motivation and energy, psychosocial, symptoms and side effects of the two groups were lower than those before treatment, and there were significant differences between the two groups after 3 months of treatment and 1 month of treatment, as well as between the two groups (all P<0.05). 【Conclusion】 Supportive expressive group psychological intervention combined with paliperidone palmitate can better improve the emotional state, restore the social function and improve the quality of life of patients with acute first-episode schizophrenia.
Key wordsSchizophrenia/DT    Acute Disease    Schizophrenic Psychology    Paliperidone Palmitate/TU
收稿日期: 2021-01-22     
中图分类号:  R749.3  
引用本文:   
赵文青. 支持性-表达性团体心理干预联合棕榈酸帕利哌酮治疗急性期首发精神分裂症患者的临床疗效[J]. 医学临床研究, 2022, 39(5): 690-692.
ZHAO Wen-qing. Clinical Efficacy of Supportive Expressive Group Psychological Intervention Combined with Paliperidone Palmitate in the Treatment of Acute First-Episode Schizophrenia. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 690-692.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.05.014     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I5/690
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn